|  |  |
| --- | --- |
|  | **CONSULTANCY** |

**Initial Terms of Reference**

This consultancy is requested by:

|  |  |
| --- | --- |
| Unit: | Innovation, Access and Use (IAU) |
| Department: | Essential Medicines and Health Products (EMP) |

1. **Purpose of the Consultancy**

The purpose of the consultancy is to assist the WHO Innovation Access and Use (IAU) Unit in the development of target product profiles (TPPs) for treatments addressing antimicrobial resistance (AMR) priority pathogens. Working closely with the WHO IAU unit, and with input from technical partners, the consultant`s role will be to prepare background documentation on TPPs for AMR priority pathogens, develop and draft the TPPs and support the management of experts meetings and inputs related to the development of the TPPs following an agreed WHO methodology.

1. **Background**

Antimicrobial resistance (AMR) is a global public health challenge. A main driver of resistance is the overuse and misuse of antibiotics in humans and animals, causing microorganisms (i.e. bacteria, fungi, viruses, and parasites) to develop resistance mechanisms, so that antimicrobial medicines (antibiotics, antifungals, antivirals, antimalarials, and anthelminthics) become ineffective to treat infections. As a response, the Sixty-eight World Health Assembly adopted the global action plan on AMR in May 2015.

New resistance mechanisms are constantly emerging and spreading globally, threatening the effective prevention and treatment of a range of infections, but also the sustainability of an effective, global public health response to the enduring threat from infectious diseases. Few replacement products are in the pipeline. Greater innovation and investment are required in the R&D of new antimicrobial therapeutics and vaccines.

Following the blueprint model, WHO published a global priority pathogen list of antibiotic-resistant bacteria of greatest public health significance, to guide R&D investments by Member States, philanthropic funders and private investors. WHO is currently reviewing antibacterial agents in clinical development, matching it against the identified priority pathogens and tuberculosis (TB), and expanding this exercise to include pre-clinical compounds.

For the priority pathogens identified, WHO is committed to developing TPPs for treatments against infections caused by priority AMR pathogens on the basis of a WHO harmonized methodology on TPPs development and in consultation with key stakeholders in the public health and scientific communities.

1. **Planned timelines** (subject to confirmation): part-time

Start date: 15/10/2018

End date: 14/10/2019

1. **Work to be performed**

Objective 1: Coordinate the development of consensus-based therapeutic TPPs for AMR priority pathogens

Deliverable 1.1: A desktop review of the background documentation for developing therapeutic TTPs for selected priority AMR pathogens, including review of technical documents as appropriate;

Deliverable 1.2: A draft of the TPPs for priority AMR pathogens, in compliance with the WHO harmonized methodology for TPPs development, for discussion with experts and other stakeholders at an expert meeting;

Deliverable 1.3: Coordinate stakeholder input into the draft TPPs;

Deliverable 1.4: Support organization of expert meetings to discuss the draft TPPs and develop a summary report of the meetings; and

Deliverable 1.5: A final draft of the TPPs for select priority AMR pathogens based on expert meeting discussions and stakeholder input.

1. **Technical Supervision**

The selected Consultant will work under the supervision of:

|  |  |  |
| --- | --- | --- |
| Responsible Officers: | Ingrid Smith | ismith@who.int |
| Manager: | Peter Beyer | beyerp@who.int |

1. **Specific requirements**

Qualifications and experience required:

* Master’s degree in a health-related field;
* At least 7 years of relevant professional experience working in the field of therapeutics research and development - with specific experience in antibiotics and in R&D targeted towards use in low and middle income countries; and
* Experience working with multiple stakeholders, including health authorities, academic institutions and industry.

Skills and knowledge:

* Capacity to interact with technical experts in public health organizations, governments, academia, and industry with respect to R&D for diagnostics and therapeutics;
* Knowledge and experience in therapeutics research and development including development of target product profiles; and
* Knowledge and experience from working on AMR related issues.

Language requirements:

* English – proficient (reading, writing, speaking)
* French - intermediate knowledge (desirable)

1. **Place of assignment**

The consultant will not be expected to work at any given location.

1. **Medical clearance**

The selected Consultant will be expected to provide a medical certificate of fitness for work.

1. **Travel**

The Consultant is expected to travel to Geneva at least monthly to WHO Headquarters in Geneva. Travel to meetings will be required.

*All* ***travel arrangements*** *will be made by WHO – WHO will not be responsible for tickets purchased by the Consultant without the express, prior authorization of WHO. While on mission under the terms of this consultancy, the Consultant will receive* ***subsistence allowance****.*

*Visas requirements: it is the consultant’s responsibility to fulfil* ***visa requirements*** *and ask for visa support letter(s) if needed.*